Clinical Research Directory

Inclusion Criteria: 1. Healthy biological females who are 18-75 years of age (inclusive). 2. Have a body mass index (BMI) between 18.5 to 39.9 kg/m2 (inclusive). 3. Have a history of recurrent, bothersome urinary tract symptom episodes. a. \* \>5 bothersome urinary tract symptom episodes in the past 6 months OR \>7 in the past 12 months will be excluded 4. Are not experiencing symptoms from a bothersome urinary tract symptom episode. 5. In good general health (no active or uncontrolled diseases or conditions) and able to consume the study product. 6. Have reliable, stable access to Wi-Fi and a smartphone/device. 7. Willing and able to agree to the requirements and restrictions of this study, willing to give voluntary consent, able to understand and read questionnaires, and able to carry out all study-related procedures. 8. English speaking. Exclusion Criteria: * 1\. Individuals who are lactating, pregnant, or planning to become pregnant during the study. 2\. Seeking enrollment in another clinical trial or active participation in a clinical trial. 3\. \>5 bothersome urinary tract symptom episodes in the past 6 months OR \>7 in the past 12 months. 4\. Use of anticoagulants (e.g., warfarin) in the past 30 days. 5. Have a known sensitivity, intolerability, or allergy to any of the study products or their excipients. 6\. History of hyperkalemia (high potassium). 7. History of Chronic Kidney Disease, kidney infections, or nephrolithiasis (kidney stones). 8\. History of hospitalization for urologic or urinary tract symptoms. 9. History of recurrent bothersome urinary tract symptom episodes accompanied by symptoms indicative of more complications, such as recurrent fever, vomiting, chills, flank pain, visible blood in urine, and pain radiating down the legs 10. Introduction of antibiotics unrelated to a urological occurrence during the study period. 11\. Current use of D-mannose. 12. Current use of cranberry supplements or cranberry juice or use of cranberry supplements of juice in 4 weeks prior to enrollment. 13\. Has previously used the Flush Advanced+ product. 14. Current use of antibiotic-based prophylaxis or use of antibiotics within 2 weeks of enrollment. 15\. History of Diabetes mellitus (Type 1 and/or 2). 16. Individuals who are immunocompromised, including those with known immunodeficiency disorders or receiving chronic immunosuppressive therapy (e.g., corticosteroids, chemotherapy, biologic agents). 17\. History of cancer within two years prior to enrollment. 18. Use of vaginal and/or local estrogen therapy (permitted if stable dose longer than 90 days). 19\. Active or suspected vaginitis. 20. Started a new nonantibiotic-based prophylaxis within the last 90 days. 21. Use of probiotics (permitted if orally administered with stable dose longer than 90 days). 22\. Use of indwelling or intermittent urinary catheterization. 23. Diagnosis of overactive bladder (OAB) or interstitial cystitis / bladder pain syndrome (IC/BPS). 24\. Urologic procedure within 6 months prior to trial enrollment or with a planned urological procedure in the 6 months following enrollment. 25\. Any urologic or gynecologic surgical history that could cause or exacerbate urinary tract symptoms. 26\. History of structural urinary tract disease or abnormalities. 27. History of Lichen sclerosis. 28. Use of potassium-sparing medications. a. E.g., Spironolactone (used for PCOS) (potassium-sparing diuretic); ACE inhibitors and ARBs; systemic calcineurin inhibitors. 39\. Use of statins. 30. Use of Vitamin C if the total daily amount consumed (including the amount in Flush Advanced+) meets or surpasses the tolerable upper intake level (UL) for adult females of 2,000 mg, per NIH guidelines 31. Use of Vitamin B6 if the total daily amount consumed (including the amount in Flush Advanced+) meets or surpasses the tolerable upper intake level (UL) for adult females of 100 mg, per NIH guidelines 32. Use of methenamine (permitted if stable dose longer than 90 days).